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Involvement of arterial system is infrequent compared with venous system. Inflammation of vasa vasorum may cause aneurysm formation, most commonly in the abdominal aorta. Thoracic aorta and pulmonary arteries are rarely affected. 2 Nevertheless, the most common cause of pulmonary artery aneurysm (PAA) is BD. 3 Intracardiac thrombus formation is an unusual complication of BD, 4 however, patients with PAA often have concomitant venous and intracardiac thrombi. 5 This condition creates therapeutic dilemma because of the risk of massive hemoptysis and emboli.
CASE REPORT
A 26-year-old man diagnosed with BD was hospitalized with cough, dyspnea, hemoptysis, and weight loss. Physical examination was non-specific except for high fever (38.2 °C), tachycardia, a painful 2x1 cm genital ulcer, and acneiform skin lesions on the back. Blood tests demonstrated an inflammatory response with elevated white blood cells (14.1¥10 Pulmonary artery aneurysm associated with intracardiac thrombus is a rare complication of Behçet's disease. In this article, we report a 26-yearold male admitted with massive hemoptysis. Pulmonary computed tomography angiogram demonstrated pulmonary artery aneurysm with thrombus. Echocardiography revealed a mobile right ventricular thrombus. The patient was treated with corticosteroids, cyclophosphamide, azathioprine, and colchicine without anticoagulant therapy. During follow-up, pulmonary artery aneurysm regressed, and no bleeding or thromboembolic event was observed.
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antibodies, and anti-neutrophil cytoplasmic antibodies were negative. Hereditary coagulation thrombophilic factors were normal.
The patient was treated with pulse steroid (intravenous methyl prednisolon 1 g/d for three days), intravenous cyclophosphamide (1 mg/kg/d), peroral azathioprine (125 mg/d) and peroral colchicine 0.5 mg/d. Peroral prednison was given after intravenous methyl prednisolon. Anticoagulation therapy was not administered. Patient was followed-up to one year. Reevaluation with pulmonary CT angiograms and echocardiograms demonstrated a remarkable regression of PAAs, and organization of intracardiac thrombus ( Figures  2b and 3b, respectively) . Currently, the patient is in a stable condition without hemoptysis or embolic event.
DISCUSSION
The concept 'vasculo-Behçet' is suggested to describe the cases in which vascular complications dominate the clinical picture. It is more common in men than in women. Early diagnosis and aggressive treatment is essential due to the unfavorable disease progress. Pulmonary artery aneurysm formation is the most lethal complication of BD. The pathologic feature of PAA is the inflammation of the vasa vasorum of pulmonary arteries which causes ischemia and weakening of vessel wall. Moreover, these lesions may open in the bronchi and cause massive hemoptysis. 6 Patients with BD are more prone to hemorrhagic complications of anticoagulation therapy due to common coincidence of aneurysms. Thrombus formation in BD is not a primary coagulation abnormality. Thrombi are caused by the inflammation of the vessel wall, and often adhered to wall having less tendency to embolize. 7 So, the incidence of pulmonary thromboembolism is very low in BD. 6 The indication of anticoagulation therapy is not clearly shown in BD and venous thrombus. 8 Treatment of PAA in BD involves combination of anti-inflammatory, and immunosuppressive agents. Prednisone, cyclophosphamide, azathioprine, cyclosporine, and tacrolimus are commonly used agents. Furthermore, tumor necrosis factor-alpha antagonist infliximab is a new agent for treatment of PAA in BD. 6, 9 The mainstay of treatment in BD is immunosuppressive therapy in patients with PAAs and intracardiac thrombus. Although there may be bleeding risks with anticoagulant therapy for patients with aneurysmal dilatation of pulmonary vessels, 10 short-term anticoagulation may be used in patients without hemoptysis. 11 Additionally, endovascular embolization may be a therapy of choice for treatment-resistant hemoptysis. 10 This case is an example demonstrating the difficulty of management of vasculo-Behçet patients with concurrent bleeding and thrombotic complications. We were able to manage our patient without any thromboembolic event, or need for endovascular embolization or emergent surgery for bleeding episode. In conclusion, this case supported an anti-inflammatory and immunosuppressive therapy without anticoagulation for BD with intracardiac thrombus and PAA.
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